Keay Nakae
Stock Analyst at Chardan Capital
(4.38)
# 358
Out of 5,124 analysts
256
Total ratings
43.85%
Success rate
25.9%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $2 | $0.33 | +503.14% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $32.55 | +7.53% | 1 | Jan 5, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $30 | $16.53 | +81.49% | 1 | Jan 5, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $3.74 | +220.86% | 19 | Dec 18, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $18.23 | +108.45% | 14 | Dec 9, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $63.88 | -6.07% | 22 | Dec 1, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.69 | +47.93% | 7 | Nov 20, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.71 | +6.16% | 14 | Nov 14, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $5.36 | +161.19% | 22 | Nov 14, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $61.73 | +62.00% | 6 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.23 | +372.81% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $7 | $8.00 | -12.50% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 | $72.06 | -0.08% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $2.04 | +96.08% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $5.93 | +490.22% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $397.83 | +0.55% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $1.88 | +165.96% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $15.19 | -60.50% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.97 | +102.02% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.58 | +1,276.70% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.19 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $18.29 | -67.20% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $2.26 | +16,714.16% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.85 | +328.02% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $5.63 | +77.62% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $22.56 | +287.85% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.45 | +796.55% | 3 | Feb 9, 2021 |
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $2
Current: $0.33
Upside: +503.14%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $32.55
Upside: +7.53%
Alto Neuroscience
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $16.53
Upside: +81.49%
SAB Biotherapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $3.74
Upside: +220.86%
Dyne Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $18.23
Upside: +108.45%
Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $60
Current: $63.88
Upside: -6.07%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.69
Upside: +47.93%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.71
Upside: +6.16%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $5.36
Upside: +161.19%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $61.73
Upside: +62.00%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.23
Upside: +372.81%
Nov 13, 2025
Downgrades: Neutral
Price Target: $25 → $7
Current: $8.00
Upside: -12.50%
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $72.06
Upside: -0.08%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.04
Upside: +96.08%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $5.93
Upside: +490.22%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $397.83
Upside: +0.55%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $1.88
Upside: +165.96%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $15.19
Upside: -60.50%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $2.97
Upside: +102.02%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.58
Upside: +1,276.70%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $18.29
Upside: -67.20%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $2.26
Upside: +16,714.16%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $12.85
Upside: +328.02%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $5.63
Upside: +77.62%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $22.56
Upside: +287.85%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.45
Upside: +796.55%